HELX - ETF AI Analysis
Top Page
Franklin Genomic Advancements ETF (HELX)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong recent gains over the past month and quarter, indicating positive momentum in its strategy.
Leading Holdings Performing Well
Several of the largest positions, including Guardant Health, Ligand Pharma, and Twist Bioscience, have delivered strong year-to-date gains that support the fund’s returns.
Focused Exposure to Genomics and Health Care
With most assets in health care and genomic-related companies, the fund offers targeted exposure to a specialized growth area in the market.
Negative Factors
High Sector Concentration
Nearly all assets are in the health care sector, so the fund is heavily exposed to swings in one industry rather than being broadly diversified.
Top Holdings Carry Significant Weight
A small group of companies makes up a large share of the portfolio, which increases the impact if any of these stocks experience setbacks.
Moderate Expense Ratio
The fund’s expense ratio is not especially low, meaning fees could take a noticeable bite out of long-term returns compared with cheaper ETFs.
HELX vs. SPDR S&P 500 ETF (SPY)
AUM33.55M
RegionGlobal
Expense Ratio0.50%
Beta0.83
IssuerFranklin
Inception DateFeb 25, 2020
Dividend Yield0.34%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume17,141
30 Day Avg. Volume6,035
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
53.09Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering66
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HELX Summary
The Franklin Genomic Advancements ETF (HELX) focuses on companies working in genetic research and advanced healthcare, rather than tracking a traditional stock index. It invests mainly in U.S. health care and biotech firms involved in gene-based testing and treatments, including well-known names like Eli Lilly and Vertex Pharmaceuticals, along with smaller, fast-growing specialists. Someone might invest in HELX to seek long-term growth from the rise of personalized medicine and new genetic therapies, while also getting a mix of established and emerging companies. A key risk is that biotech and genomics stocks can be very volatile and may rise or fall sharply with news and market sentiment.
How much will it cost me?The Franklin Genomic Advancements ETF (HELX) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche in genomic advancements, which requires more research and expertise compared to passively managed funds.
What would affect this ETF?The Franklin Genomic Advancements ETF (HELX) could benefit from growing interest in personalized medicine and advancements in genetic research, as well as increased healthcare spending globally. However, it may face challenges from regulatory hurdles in biotechnology, potential setbacks in clinical trials, and broader economic pressures that could impact funding for innovation. Its heavy focus on healthcare and genomic advancements makes it sensitive to both breakthroughs and disruptions in this niche sector.
HELX Top 10 Holdings
HELX is essentially a pure play on cutting-edge genomics, with heavy exposure to U.S.-listed health care innovators. Natera and Guardant Health are doing much of the heavy lifting, with their stocks steadily rising on optimism around precision oncology. Adaptive Biotechnologies and Ligand Pharma add more fuel to the theme, showing generally constructive momentum despite ongoing profitability worries. On the flip side, Krystal Biotech and BridgeBio Pharma have been more mixed to lagging lately, occasionally acting as speed bumps for the fund’s otherwise strong genomics-driven trajectory.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Natera | 10.40% | $3.47M | $57.34B | 128.95% | 73 Outperform | |
| Guardant Health | 9.39% | $3.14M | $21.85B | 159.09% | 61 Neutral | |
| Krystal Biotech | 5.23% | $1.75M | $9.83B | 70.78% | 80 Outperform | |
| Ligand Pharma | 4.62% | $1.54M | $6.20B | 67.77% | 60 Neutral | |
| Adaptive Biotechnologies | 4.50% | $1.50M | $4.08B | 62.26% | 53 Neutral | |
| Twist Bioscience | 4.39% | $1.46M | $10.00B | 395.35% | 43 Neutral | |
| BridgeBio Pharma | 2.85% | $949.69K | $12.85B | 12.04% | 59 Neutral | |
| Medpace Holdings | 2.76% | $920.32K | $17.31B | 17.98% | 79 Outperform | |
| United Therapeutics | 2.66% | $887.92K | $23.59B | 25.32% | 79 Outperform | |
| Vertex Pharmaceuticals | 2.57% | $856.41K | $128.50B | 17.71% | 78 Outperform |
HELX Technical Analysis
Positive
―
Price Trends
42.44
Positive
40.16
Positive
37.31
Positive
Market Momentum
-0.04
Positive
49.25
Neutral
13.87
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HELX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 43.28, equal to the 50-day MA of 42.44, and equal to the 200-day MA of 37.31, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.25 is Neutral, neither overbought nor oversold. The STOCH value of 13.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HELX.
HELX Peer Comparison
Comparison Results
Performance Comparison
HELX
Franklin Genomic Advancements ETF
42.59
9.33
28.05%
BLDX
Impax Global Infrastructure ETF
―
―
―
FFND
Future Fund Active ETF
―
―
―
IQM
Franklin Intelligent Machines ETF
―
―
―
HECO
SPDR Galaxy Hedged Digital Asset Ecosystem ETF
―
―
―
GNMX
Corgi Genomics & Precision Medicine ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents